DuBrock HM, Nathan SD, Reeve BB, Kolaitis NA, Mathai SC, Classi PM, Nelsen AC, Olayinka-Amao B, Norcross LN, Martin SA. Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life. Pulm Circ. 2021 Apr 1;11(2):204589402. doi: 10.1177/20458940211005641
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Brown TM, Holland J, Bokowy KL, Horblyuk R. Can transformational programs aimed at improving hospital management, leadership, and productivity systems affect financial performance? J Hospital Admin. 2013 Jul 30;2(4):111-9.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
McKenna SP, Whalley D, Doward LC. Which outcomes are important in schizophrenia? Int J Methods Psychiatr Res. 2000;9(1):S58-67.